Flow Forward Medical Inc. today announced that it has closed a $1.3 million round of additional Series A financing, led by existing investor, the Kansas Bioscience Authority (KBA).
Traverse Biosciences announced that it has executed a $250,000 cooperative research and development agreement (CRADA) with Aratana Therapeutics Inc. (NASDAQ:PETX) to advance the development of TRB-N0224 for the treatment and control of periodontal disease in companion animals, including dogs and cats.
KBA's Tony Simpson joins top agricultural and life science executives to support emerging era of animal agriculture –
rapid, on-farm diagnostics for early disease detection
Metactive Medical Inc. today announced that it has closed on $2 million of additional Series A financing, led by the Kansas Bioscience Authority (KBA), an existing Metactive investor.
By Alyssa Scott, KU Statehouse Wire Service
New investors join in support of diagnostic solutions that benefit the food supply
Aratana Therapeutics Inc. has finalized a global licensing agreement with Ukraine-based Atopix Therapeutics Ltd. to develop and commercialize a drug for dogs to treat atopic dermatitis, also known as eczema.
The InvestMidwest Venture Capital Forum is accepting applications from entrepreneurs with high-growth companies ho
Johnston, Iowa, USA—Biova LLC, the world leader for water soluble egg membrane ingredients, has expanded their cutting-edge technology into a new neighborhood.The new Biova office at 10900 S.Clay
Aratana Therapeutics Inc. announced Wednesday it will offer 4.5 million shares of its common stock at $9.25 a share, which would raise abou
LAWRENCE, KS – CritiTech, Inc. has named Mechanical Systems, Inc. (MSI) of Wichita, Kan., as its official and exclusive supplier of fine-particle drug manufacturing equipment.
August 25, 2014 – The Kansas City Animal Health Corridor has released new evidence of the global impact of the KC region’s animal health industry concentration. Companies with a strategic location in the KC Animal Health Corridor now represent 56 percent of total worldwide animal health, diagnostics and pet food sales.
Mission, Kansas - EMCI is proud to announce that the FlexiLume Dental LED System has received regulatory clearance for sale worldwide, including FDA approval and CE mark.Peter Lucas, COO of EMCI,
Heartland Plant Innovations (HPI) has announced the hiring of Dr. Muhammad Asif as its new Chief Scientist. Asif will be charged with leading HPI’s scientific efforts including novel trait development as well as the Advanced Plant Breeding Services. HPI offers wheat doubled haploids, wide hybridization/trait introgression, and genotyping as services to customers world-wide. All services are provided without claim to intellectual property which makes HPI attractive to wheat breeders working on advanced germplasm.
Aratana Therapeutics, Inc., a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, today announced its second quarter 2014 results.
LAWRENCE, KS – CritiTech, Inc., a growing drug delivery and development company, announced today that it has entered into a collaboration with European Medical Contract Manufacturing (EMCM) of Nijmegen, Netherlands, to develop tissue grafts coated with a variety of drugs using CritiTech’s proprietary supercritical fluid technology. The coated tissue grafts are being developed to provide effective and long-lasting antimicrobial control and rapid healing, especially in revision surgeries, to compensate for and correct failed implants.
LAWRENCE, KS – CritiTech, a growing drug delivery and development company, announced today positive results from the Phase I Trial of Nanotax® (“Trial”), a novel fine particle reformulation of paclitaxel to treat intraperitoneal cancers.
Metactive Wins First Prize at the Medical Device Entrepreneur's Forum at the ASAIO 60th Annual Conference
OLATHE, Kan. Metactive Medical, Inc. ("Metactive") announced that it was awarded top prize in a business plan competition hosted by the Medical Device Entrepreneur's Forum, a special session held on June 20, 2014 at the ASAIO 60th Annual Conference in Washington, DC.
Aratana Therapeutics Initiates and Doses First Patient in Market Development Studies of AT-005 for Treating Canine T-cell Lymphoma
KANSAS CITY, Kan., Aratana Therapeutics, Inc., a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it is currently enrolling patients in two nationwide clinical trials to evaluate its monoclonal antibody for canine T-cell lymphoma, AT-005, which is conditionally licensed by the USDA to aid in the treatment of dogs with lymphoma.
Lenexa, KS – IGXBio, Inc. has received approval from U.S. Food and Drug Administration (FDA) to begin human clinical trials of GenePro®, a DNA-based HIV vaccine.
Aratana Therapeutics Inc.
Flow Forward Medical, Inc., an early-stage medical device company focused on improving outcomes for hemodialysis patients through the rapid creation of high-quality vascular access sites, today an
KANSAS CITY, Kan., -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing an
Metactive Medical, Inc., an early-stage company focused on developing endovascular embolization devices for the treatment of neurovascular and peripheral vascular diseases, today presented new non
Terratek® Flex, the market’s first compostable elastomeric bioplastic, can be used as an impact modifier for polylactic acid (PLA), increasing impact strength, elongation and flexibility without s
Health Outcomes Sciences Inc. (HOS), a leading healthcare IT company based in Overland Park, Kan., today announced that it has completed the first close of its Series A Preferred financing round. The company has raised $5 million in the first closing and expects to raise up to an additional $2 million of capital, bringing the round to $7 million.
Metactive Medical, Inc., an early-stage company focused on developing embolization devices for the treatment of peripheral vascular and neurovascular diseases, today announced that it has launched
Aratana Therapeutics Inc.
Virginia-based Health Diagnostic Laboratory, Inc. will acquire and operate Oncimmune’s DeSoto, Kansas lab and become the exclusive licensed U.S. provider of EarlyCDT®- Lung, the world’s first autoantibody test for early detection of lung cancer.
OLATHE, Kan. (February 6, 2013) – Aratana Therapeutics is the recipient of a $324,148 investment by the Kansas Bioscience Authority. Previously code-named “Project Gray,” the funding was unanimously approved by the Board of Directors on January 22, 2013. Aratana requested that the details of this investment be kept confidential until the fundraising round closed.